ACABRUNAT is recommended for patients diagnosed with CLL (chronic lymphocytic leukemia) or MCL (mantle cell lymphoma), particularly when targeted treatment is required or prior therapies were ineffective. Acalabrutinib works by inhibiting BTK, a critical enzyme in B-cell signaling, thereby blocking the growth and survival of malignant cells.
– Chronic Lymphocytic Leukemia (CLL)
– Mantle Cell Lymphoma (MCL)
The medication is taken orally at a dose of 100 mg twice daily, with or without food. The course and duration of treatment are determined by a healthcare provider based on the patient's condition.
Contraindicated in patients allergic to Acalabrutinib, during pregnancy, and while breastfeeding. Possible side effects include headache, diarrhea, infections, and hematologic abnormalities. Regular medical supervision is essential during treatment.
